Geron Corporation (GERN): Price and Financial Metrics


Geron Corporation (GERN): $1.77

-0.02 (-0.84%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add GERN to Watchlist
Sign Up

Industry: Biotech


Ranked

of 485

in industry

GERN Stock Summary

  • With a price/sales ratio of 1,477.65, Geron Corp has a higher such ratio than 99.4% of stocks in our set.
  • With a year-over-year growth in debt of 8,404.01%, Geron Corp's debt growth rate surpasses 99.56% of about US stocks.
  • Revenue growth over the past 12 months for Geron Corp comes in at -43.68%, a number that bests just 7.59% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to GERN, based on their financial statements, market capitalization, and price volatility, are MRSN, BBIO, ATHX, CRNX, and CRDF.
  • Visit GERN's SEC page to see the company's official filings. To visit the company's web site, go to www.geron.com.

GERN Stock Price Chart Interactive Chart >

Price chart for GERN

GERN Price/Volume Stats

Current price $1.77 52-week high $2.40
Prev. close $1.78 52-week low $0.75
Day low $1.71 Volume 1,699,540
Day high $1.81 Avg. volume 3,981,336
50-day MA $1.78 Dividend yield N/A
200-day MA $1.83 Market Cap 547.98M

Geron Corporation (GERN) Company Bio


Geron Corporation focuses on the development of telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. The company was founded in 1990 and is based in Menlo Park, California.


GERN Latest News Stream


Event/Time News Detail
Loading, please wait...

GERN Latest Social Stream


Loading social stream, please wait...

View Full GERN Social Stream

Latest GERN News From Around the Web

Below are the latest news stories about Geron Corp that investors may wish to consider to help them evaluate GERN as an investment opportunity.

Geron to Announce Fourth Quarter and Full Year 2020 Financial Results on March 11, 2021

Geron Corporation (Nasdaq: GERN) today announced that it will release its fourth quarter and full year 2020 financial results after the market closes on Thursday, March 11, 2021 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as recent events at 4:30 p.m. ET the same day.

Yahoo | March 1, 2021

Is Geron (NASDAQ:GERN) Weighed On By Its Debt Load?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Yahoo | February 7, 2021

Geron to Present at the B. Riley Securities Virtual Oncology Investor Conference

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, will present a company overview at the B. Riley Securities Virtual Oncology Investor Conference on Wednesday, January 20, at 3:00 p.m. ET. A live audio webcast of the presentation will be available on Geron’s website, www.geron.com/investors/events. A replay of the webcast will be available on

Business Wire | January 14, 2021

Is GERN A Good Stock To Buy Now?

Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that’s why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]

Yahoo | December 17, 2020

Protocol hires WSJ's Geron to cover financial technology - Talking Biz News

Tech news site Protocol has hired Wall Street Journal reporter Tomio Geron to cover financial technology. He has been writing about technology, venture capital and startups for WSJ Pro Venture Capital and The Wall Street Journal…

Talking Biz News | December 11, 2020

Read More 'GERN' Stories Here

GERN Price Returns

1-mo -6.84%
3-mo -0.56%
6-mo -3.28%
1-year 56.64%
3-year -30.31%
5-year -39.80%
YTD 11.32%
2020 16.91%
2019 36.00%
2018 -44.44%
2017 -13.04%
2016 -57.23%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7386 seconds.